发明名称 |
Controlled release oxycodone compositions |
摘要 |
<p>A method for substantially reducing the range in daily dosages required to control pain in approximately 80% of patients is disclosed whereby an oral solid controlled release dosage formulation having from about 10 to about 40 mg-of oxycodone or a salt thereof is administered to a patient. The formulation provides a mean maximum plasma concentration of oxycodone from about 6 to about 60 ng/ml from a mean of about 2 to about 4.5 hours after administration, and a mean minimum plasma concentration from about 3 to about 30 ng/ml from about 10 to about 14 hours after repeated "q12h" (i.e., every 12 hours) administration through steady-state conditions. Another embodiment is directed to a method for substantially reducing the range in daily dosages required to control pain in substantially all patients. The figure is a graph showing the mean plasma oxycodone concentration for a 10 mg controlled release oxycodone formulation prepared in accordance with the present invention and a study reference standard.</p> |
申请公布号 |
EP2340833(A2) |
申请公布日期 |
2011.07.06 |
申请号 |
EP20100181156 |
申请日期 |
1992.11.25 |
申请人 |
NAPP PHARMACEUTICAL HOLDINGS LIMITED |
发明人 |
OSHLACK, BENJAMIN;CHASIN, MARK;MINONGUE, JOHN JOSEPF;KAIKO, ROBERT, F. |
分类号 |
A61K9/16;A61K31/485;A61K;A61K9/20;A61K9/22;A61K9/26;A61K9/28;A61K9/30;A61K9/50;A61K9/58;A61K47/30;A61K47/32;A61K47/38;A61P;A61P25/04 |
主分类号 |
A61K9/16 |
代理机构 |
|
代理人 |
|
主权项 |
|
地址 |
|